Global Bioenergies: First milestone hit in BioMA+ project

06-Feb-2015 - Global Bioenergies announces having reached the first milestone of the BioMA+ project which is financed by the French "Investissements d'Avenir" State program. The project aims at developing a renewable value chain to methacrylic acid, a key constituent of acrylic paints. Achieving this first ...

Evolva announces collaboration with L’Oréal

11-Feb-2014 - Evolva Holding SA announced that it has signed a collaboration agreement with L’Oréal for the co-development of novel biosynthetic production routes for an undisclosed ingredient with broad applications in the cosmetics industry. Evolva and L’Oréal will apply Evolva’s fermentation technology ...

Evolva reaches milestone in BASF collaboration

31-Jan-2013 - Evolva Holding SA announced that it has achieved a key milestone in its collaboration with BASF. The collaboration involves joint research on the design of novel and optimised biosynthetic routes for a natural product with crop protectionpotential. Evolva has produced a yeast strain that ...

Evolva reaches first milestone in IFF collaboration

22-Jun-2012 - Evolva Holding SA announced that International Flavors & Fragrances Inc. (IFF) has confirmed that Evolva has achieved the first milestone in their collaboration that was announced in January 2011. The ultimate objective of the collaboration is to implement a commercially viable biosynthetic route ...

Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate

08-Jan-2008 - Pfizer Inc and Taisho Pharmaceutical Co., Ltd. have signed a definitive agreement, which replaces the letter of intent previously signed between the companies, for worldwide (excluding Japan) collaboration to research, develop and commercialize TS-032, a new schizophrenia drug candidate ...

Acambis signs JE partnership agreement with sanofi pasteur

16-Feb-2007 - Acambis plc announced a partnership agreement with sanofi pasteur, the vaccines business of the sanofi-aventis Group, for ChimeriVax(TM)-JE, Acambis' single-dose vaccine against Japanese encephalitis (JE). Under the agreement, Acambis has granted sanofi pasteur marketing, distribution and ...

Solvay and Wyeth collaborate for discovery of anti-psychotics with novel mechanisms

Expansion of existing neuroscience agreement

15-Jan-2007 - Solvay Pharmaceuticals and Wyeth Pharmaceuticals announced that they are expanding their existing neuroscience co-development, and co-commercialization agreement to include research in neuroscience. The neuroscience co-development and co-commercialisation partnership already announced in April ...

Bayer CropScience acquires rights to FMC Corporation´s insecticides discovery pipeline

29-Jun-2006 - Bayer CropScience AG and FMC Corporation announced that Bayer CropScience has acquired the rights to FMC's insecticides discovery pipeline. The agreement enables Bayer CropScience to discover and commercialize new insecticidal compounds from the discovery pipeline. In return FMC will receive ...

Flamel Technologies Announces Receipt of Milestone from GlaxoSmithKline

23-May-2006 - Flamel Technologies announced that it has received a $1 million milestone from its collaborator, GlaxoSmithKline. The milestone payment was triggered by successful completion of activities relating to the manufacturing process for Coreg CR(TM) microparticles. Flamel and GSK completed a supply ...

Alkermes and Lilly Announce Agreement for the Development and Commercialization of Inhaled Parathyroid Hormone

11-Jan-2006 - Alkermes, Inc. and Eli Lilly and Company announced that they have signed an agreement to develop and commercialize inhaled formulations of parathyroid hormone (PTH). The development program will utilize the Alkermes AIR® pulmonary drug delivery system. Lilly's recombinant PTH, Forteo® ...